Opendata, web and dolomites

EMODI SIGNED

Epithelial resistance modulation to treat disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "EMODI" data sheet

The following table provides information about the project.

Coordinator
FACULDADE DE CIENCIAS MEDICAS DA UNIVERSIDADE NOVA DE LISBOA 

There are not information about this coordinator. Please contact Fabio for more information, thanks.

 Coordinator Country Portugal [PT]
 Total cost 147˙500 €
 EC max contribution 147˙500 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2015-PoC
 Funding Scheme ERC-POC
 Starting year 2016
 Duration (year-month-day) from 2016-10-01   to  2018-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSIDADE NOVA DE LISBOA PT (LISBOA) coordinator 147˙500.00
2    FACULDADE DE CIENCIAS MEDICAS DA UNIVERSIDADE NOVA DE LISBOA PT (LISBOA) coordinator 0.00

Map

 Project objective

Epithelial barriers are essential for organism’s homeostasis and survival. Defects in resistance of body barrier epithelial tissues and their repair are thought to underlie a range of diseases, which affect millions. Antonio Jacinto’s group has discovered that Septate/Tight Junctions are essential for epithelial repair. These cell-cell junctions can be potentially targeted by candidate compounds that have been identified by Thelial, a Start-Up that will collaborate in this project. In EMODI we will complete preclinical proof of concept of the potential therapeutic activity of two selected compounds, relying on scientific results and technologies developed under ERC starting grant awarded to Dr. Antonio Jacinto. Regarding clinical application, we will focus on rare (orphan) diseases which have been associated to impaired epithelial repair in the gastro-intestinal track for which there are very limited treatment options: Sjoergen Syndrome (SjS) and Eosinophilic Esophagitis (EoE). The plan of activities involves the following steps: 1) Biological efficacy testing of the-1 and the-2 in a zebrafish Tight Junction model and in mouse models of the diseases under focus; 2) Development of IPR based on the biological testing; 3) Consolidate outcomes of steps 1 and 2 into a business plan; 4) Present the business plan to VC funds to seek for extra round of funding. The long-term aim is clinical development of our candidates not only in the context of SjS and EoE but also towards a range of o diseases where impaired epithelial barrier function is impaired and a cause of morbidity.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EMODI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EMODI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

EVOMENS (2020)

The evolution of menstruation in primates

Read More  

DISINTEGRATION (2019)

The Mass Politics of Disintegration

Read More  

InsideChromatin (2019)

Towards Realistic Modelling of Nucleosome Organization Inside Functional Chromatin Domains

Read More